How short steroid treatments change bone turnover markers in people with inflammatory joint disease
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study
This project will test whether short courses of glucocorticoids change blood bone-turnover tests in people with inflammatory joint disease who are not on osteoporosis therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 25 Years to 90 Years |
| Sex | All |
| Sponsor | Diakonhjemmet Hospital Academic / other |
| Locations | 2 sites (Drammen and 1 other locations) |
| Trial ID | NCT06395883 on ClinicalTrials.gov |
What this trial studies
This observational study follows patients with inflammatory rheumatic joint disease who either start disease-modifying therapy with or without short-term glucocorticoids or receive a parenteral glucocorticoid injection while on stable DMARDs. Blood bone-turnover markers (BTMs) will be measured before, during, and after the short glucocorticoid exposure to document the size and timing of changes. Patients with prior osteoporosis, recent fractures, chronic steroid use, active cancer, or kidney failure are excluded to avoid confounding. The goal is to define how reliably BTMs reflect bone metabolism surrounding short steroid courses to guide clinical interpretation and management.
Who should consider this trial
Good fit: Adults with an inflammatory rheumatic joint disease who need short-term glucocorticoid treatment or parenteral glucocorticoid injection and are not on osteoporosis medication, without recent fractures or chronic steroid use, are ideal candidates.
Not a fit: People already diagnosed with osteoporosis or on osteoporosis treatment, those with chronic glucocorticoid use, recent fractures, active cancer, kidney failure, or women in the transitory phase are excluded and unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the results could help clinicians interpret BTM blood tests around steroid use and improve osteoporosis care and fracture prevention.
How similar studies have performed: Previous research shows glucocorticoids substantially suppress BTMs (often by ~30%), but the timing and recovery after short steroid courses is not well defined.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of inflammatory rheumatic joint disease * indication of disease modifying treatment initiation with or without glucocorticoids OR * stable DMARD treatment with parenteral glucocorticoid injection Exclusion Criteria: * known osteoporosis or osteoporosis treatment * women during the transitory phase * oestrogen treatment * any fracture within the last year * chronic glucocorticoid treatment * glucocorticoid treatment within the last year prior to inclusion * active cancer * kidney failure
Where this trial is running
Drammen and 1 other locations
- Vestre Viken HF, Drammen — Drammen, Norway (Recruiting)
- Diakonhjemmet hospital — Oslo, Norway (Recruiting)
Study contacts
- Study coordinator: Birgitte Nellemann Nellemann, MD PHD
- Email: birgittenellemann@gmail.com
- Phone: +4747957020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.